

Demographics and Baseline Characteristics (Age, Height and Weight) by Treatment

TREATMENT START DATE


09-07-201202-09-2014

AGE

5189


SUBJECT COUNT by BMI LEVELS and SEX

BMI LEVELS 12 15 18 21 24 27 30 33 36 39




SUBJECT COUNT by HEIGHTS and SEX

HEIGHTS 130 140 150 160 170 180 190




SUBJECT COUNT by WEIGHTS and SEX


WEIGHTS 30 45 60 75 90 105




SUBJECT COUNT by BMI LEVELS



SUBJECT COUNT by HEIGHTS and SEX



SUBJECT COUNT by WEIGHTS



Demographics (Age Groups, Race, Ethnicity)

TREATMENT START DATE

09-07-2012

02-09-2014

AGE

51


89

BMI LEVEL


13.70

40.10

SUBJECT COUNT by TREATMENTS



SUBJECT COUNT




RACE	HISPANIC OR LATINO	NOT HISPANIC OR LATINO	Total
AMERICAN INDIAN OR ALASKA NATIVE		1	1
BLACK OR AFRICAN AMERICAN		23	23
WHITE	12	217	229
Total	12	241	253

AMERICAN INDIAN OR ALASKA NATIVE


WHITE

BLACK OR AFRICAN AMERICAN

SUBJECT COUNT by AGE GROUPS and SEX




SUBJECT COUNT by AGE GROUPS




SUBJECT ID	AGE
01-701-1015	63
01-701-1023	64
01-701-1028	71
01-701-1033	74
01-701-1034	77
01-701-1047	85
01-701-1097	68
01-701-1111	81
01-701-1115	84
01-701-1118	52
01-701-1130	84
01-701-1133	81
01-701-1146	75
01-701-1148	57
01-701-1153	79
01-701-1180	56
01-701-1181	79
01-701-1188	71
01-701-1192	80

Overview of TEAEs (Treatment Emergent Adverse Events) and event rate

SUBJECT COUNT (%) by DISPOSITION REASONS



BMI LEVEL



AGE




SUBJECT COUNT (%) by END OF STUDY STATUS



SUBJECT ID


- 01-701-1015
- 01-701-1023
- 01-701-1047
- 01-701-1097
- 01-701-1111
- 01-701-1115
- 01-701-1130
- 01-701-1146
- 01-701-1148
- 01-701-1153
- 01-701-1180
- 01-701-1181
- 01-701-1192
- 01-701-1203
- 01-701-1211

SUBJECT COUNT (%) by ADVERSE EVENT OUTCOMES




Distribution of days on study to AE (Adverse Events) onset for subjects with AE (Adverse Events)

SUBJECT COUNT by GROUPS (STARTING DAYS) and SEX



SUBJECT COUNT by GROUPS (ENDING DAYS) and SEX



SUBJECT ID	RACE	AGE	TREATMENT
01-701-1015	WHITE	63	TRT A
01-701-1023	WHITE	64	TRT A
01-701-1047	WHITE	85	TRT A
01-701-1097	WHITE	68	TRT C
01-701-1111	WHITE	81	TRT C
01-701-1115	WHITE	84	TRT C
01-701-1130	WHITE	84	TRT A
01-701-1146	WHITE	75	TRT B
01-701-1148	WHITE	57	TRT B
01-701-1153	WHITE	79	TRT A
01-701-1180	WHITE	56	TRT B
01-701-1181	WHITE	79	TRT B
01-701-1192	WHITE	80	TRT C
01-701-1203	BLACK OR AFRICAN AMERICAN	81	TRT A
01-701-1211	WHITE	76	TRT C
01-701-1239	WHITE	56	TRT B
01-701-1275	AMERICAN INDIAN OR ALASKA NATIVE	61	TRT B
01-701-1287	WHITE	56	TRT B
01-701-1294	WHITE	67	TRT C
01-701-1302	WHITE	61	TRT B
01-701-1324	WHITE	79	TRT C
01-701-1341	WHITE	51	TRT C
01-701-1363	BLACK OR AFRICAN AMERICAN	81	TRT A
01-701-1383	WHITE	72	TRT B
01-701-1387	WHITE	87	TRT A
01-701-1392	WHITE	78	TRT A

Distribution of BMI (Body Mass Index) across visits

BMI LEVEL

13.70

40.10




AGE

51

89




SUBJECT COUNT by VISITING WEEKS




SUBJECT COUNT by BMI LEVELS, SEX and TREATMENTS

SEX ● F ● M




SUBJECT COUNT by BMI LEVELS and SEX




Additional Findings on Average Daily Doses and Treatment Duration


AGE



BMI LEVEL




SUBJECT COUNT by TREATMENTS




SUBJECT COUNT (%) by TREATMENT DURATION and TREATMENTS

TREATMENTS ● TRT A ● TRT B ● TRT C




AVERAGE DAILY DOSE by HEIGHTS and SEX

SEX ● F ● M



AVERAGE DAILY DOSE by WEIGHTS and SEX

SEX ● F ● M



AVERAGE DAILY DOSE by AGE GROUPS

